

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2025

**BioXcel Therapeutics, Inc.**  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation)

001-38410  
(Commission File Number)

82-1386754  
(I.R.S. Employer  
Identification No.)

555 Long Wharf Drive  
New Haven, CT 06511  
(Address of principal executive offices, including Zip Code)

(475) 238-6837  
(Registrant's telephone number, including area code)

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001	BTAI	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events.**

On August 14, 2025, BioXcel Therapeutics, Inc. (the “Company”) received positive preliminary meeting comments from the U.S. Food and Drug Administration (FDA) related to the pre-sNDA meeting scheduled for August 20, 2025. The Company is evaluating the feedback from the FDA and plans to provide an update next week.

The primary purpose of the planned pre-sNDA meeting is to gain alignment with the FDA regarding the proposed format and content of the Company’s planned sNDA submission, including the clinical, nonclinical and chemistry, manufacturing and controls (CMC) requirements.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 15, 2025

**BIOXCEL THERAPEUTICS, INC.**

/s/ Richard Steinhart  
By: Richard Steinhart  
Title: Chief Financial Officer

---